explore -WSS

explore

author：Wikipedia 2025-09-02 08:22:11 - browse：3

Alphabet’s life sciences company Verily has scored its first Centers for Disease Control and Prevention contract, a high profile job leaders hope will boost its brand in public health as well as its nascent wastewater surveillance business, executives told STAT.

Under the up-to-five year, $38 million contract, Verily will collect samples from hundreds of wastewater treatment centers across the country, analyze them for Covid-19 and the mpox virus at its South San Francisco lab, and return the data to CDC within 36 hours of collecting the samples. The contract is limited to those two pathogens but the company is prepared to analyze more if needed, leaders said.

The contract comes as Verily struggles to turn a profit among various disparate health care offerings, like value-based care analytics for health systems, clinical trial software and even an in-person substance use rehabilitation center in Ohio. Despite several prominent hires and a vast number of projects, the company has yet to forge a sustainable business.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Grad students accuse University of California of wage theft

WSS

Vertex non

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Why Medicare shouldn’t cover every FDA

FDA weighs limits of animal data in assessing artificial wombs

Philips to halt sales of sleep apnea machines in U.S.

Venture capital firm's plans to take over Akron hospital face hurdles

hotspot

explore

hotspot

Bright Health sells Medicare Advantage business to Molina

Zyn nicotine pouches become unlikely player in latest culture war

Cancer drug shortages should be causing more outrage

Covid’s new normal has set in amid another rise in cases

At least 13 dead in Texas as scorching temps continue

What happened to the House vote on health price transparency?

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

At least 13 dead in Texas as scorching temps continue

Covid’s new normal has set in amid another rise in cases

leisure time

Medicare Advantage insurers face 0.2% cut to 2025 payments

How the messy conversation about Dolly changed bioethics

Biogen walks away from Aduhelm, years after polarizing approval

Biogen walks away from Aduhelm, years after polarizing approval

FTC sues over Novant Health acquisition of two N.C. hospitals

Vertex non

hotspot

Wikipedia

explore

focus